ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2026)

ARS Pharmaceuticals has reported FCF Margin for 5 years, with the latest figure at 198.17% in Q1 2026.

• Quarterly FCF Margin rose 31398.0% year-over-year to 198.17% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 177.11% (down 15544.0% YoY) and the FY2025 annual result came in at 203.14%, down 21771.0% from the prior year.
• FCF Margin eased to 198.17% in Q1 2026 per SPRY's latest filing, from 154.82% in the prior quarter.
• Over five years, FCF Margin peaked at 48.17% in Q4 2024 and troughed at 165670.0% in Q2 2023.
• A 5-year average of 18287.87% and a median of 712.19% in 2024 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2023 and 2024: FCF Margin tumbled 16416224 bps in 2023, then jumped 16423080 bps in 2024.
• Over 5 years, FCF Margin stood at 3022.22% in 2022, then slumped by 5382 bps to 165670.0% in 2023, then jumped by 100 bps to 48.17% in 2024, then plunged by 421 bps to 154.82% in 2025, then decreased by 28 bps to 198.17% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 198.17%, 154.82%, and 127.77% for Q1 2026, Q4 2025, and Q3 2025 respectively.